Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cetuximab + Mobocertinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cetuximab||Erbitux||IMC-C225||EGFR Antibody 53||Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).|
|Mobocertinib||Exkivity||TAK-788|TAK788|AP32788|AP-32788|AP 32788||EGFR Inhibitor (Pan) 60 HER2 Inhibitor 40||Exkivity (mobocertinib) inhibits EGFR and ERBB2 (HER2), with selectivity for mutant forms including EGFR exon 20 insertions, potentially resulting in growth inhibition in EGFR or ERBB2-mutant cancer cells (PMID: 33632775). Exkivity (mobocertinib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations after disease progression on platinum-based chemotherapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|